{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T03:16:41Z","timestamp":1781839001798,"version":"3.54.5"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T00:00:00Z","timestamp":1708387200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.radonc.2024.110181","type":"journal-article","created":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T22:12:13Z","timestamp":1708726333000},"page":"110181","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["ONE SHOT - single shot radiotherapy for localized prostate cancer: 18-month results of a single arm, multicenter phase I\/II trial"],"prefix":"10.1016","volume":"194","author":[{"given":"Thomas","family":"Zilli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciro","family":"Franzese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Guckenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niccol\u00f2","family":"Giaj-levra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Mach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Koutsouvelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Verane","family":"Achard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Mcdonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Alongi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Scorsetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Constantin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurelie","family":"Bertaut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond","family":"Miralbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2024.110181_b0005","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1016\/j.ijrobp.2010.10.075","article-title":"Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: alpha\/beta = 1.4 (0.9-2.2) Gy","volume":"82","author":"Miralbell","year":"2012","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"key":"10.1016\/j.radonc.2024.110181_b0010","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1200\/JCO.2016.71.7397","article-title":"Randomized Trial of a Hypofractionated Radiation Regimen for the Treatment of Localized Prostate Cancer","volume":"35","author":"Catton","year":"2017","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.radonc.2024.110181_b0015","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/S1470-2045(16)30102-4","article-title":"Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial","volume":"17","author":"Dearnaley","year":"2016","journal-title":"The Lancet Oncology"},{"key":"10.1016\/j.radonc.2024.110181_b0020","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.radonc.2014.01.008","article-title":"A modelled comparison of prostate cancer control rates after high-dose-rate brachytherapy (3145 multicentre patients) combined with, or in contrast to, external-beam radiotherapy","volume":"111","author":"Roberts","year":"2014","journal-title":"Radiotherapy and Oncology"},{"key":"10.1016\/j.radonc.2024.110181_b0025","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.semradonc.2008.04.004","article-title":"The linear-quadratic model is an appropriate methodology for determining isoeffective doses at large doses per fraction","volume":"18","author":"Brenner","year":"2008","journal-title":"Seminars in Radiation Oncology"},{"key":"10.1016\/j.radonc.2024.110181_b0030","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.radonc.2013.09.005","article-title":"Applicability of the linear-quadratic formalism for modeling local tumor control probability in high dose per fraction stereotactic body radiotherapy for early stage non-small cell lung cancer","volume":"109","author":"Guckenberger","year":"2013","journal-title":"Radiotherapy and Oncology"},{"key":"10.1016\/j.radonc.2024.110181_b0035","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.clon.2021.12.006","article-title":"Ultrahypofractionated Radiotherapy for Localised Prostate Cancer: How Far Can We Go?","volume":"34","author":"Corkum","year":"2022","journal-title":"Clinical Oncology (Royal College of Radiologists)"},{"key":"10.1016\/j.radonc.2024.110181_b0040","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.ijrobp.2019.03.051","article-title":"Stereotactic Body Radiation Therapy for Localized Prostate Cancer: A Systematic Review and Meta-Analysis of Over 6,000 Patients Treated On Prospective Studies","volume":"104","author":"Jackson","year":"2019","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"key":"10.1016\/j.radonc.2024.110181_b0045","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1016\/S1470-2045(22)00517-4","article-title":"Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial","volume":"23","author":"Tree","year":"2022","journal-title":"The Lancet Oncology"},{"key":"10.1016\/j.radonc.2024.110181_b0050","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(19)31131-6","article-title":"Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial","volume":"394","author":"Widmark","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.radonc.2024.110181_b0055","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1016\/j.ijrobp.2023.08.027","article-title":"5-Year Outcomes from PACE B: An International Phase III Randomized Controlled Trial Comparing Stereotactic Body Radiotherapy (SBRT) vs. Conventionally Fractionated or Moderately Hypo Fractionated External Beam Radiotherapy for Localized Prostate Cancer","volume":"117","author":"van As","year":"2023","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"key":"10.1016\/j.radonc.2024.110181_b0060","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.radonc.2016.04.006","article-title":"High-dose-rate interstitial brachytherapy as monotherapy in one fraction for the treatment of favorable stage prostate cancer: Toxicity and long-term biochemical results","volume":"119","author":"Prada","year":"2016","journal-title":"Radiotherapy and Oncology"},{"key":"10.1016\/j.radonc.2024.110181_b0065","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.ijrobp.2019.02.010","article-title":"Five-Year Outcomes of a Single-Institution Prospective Trial of 19-Gy Single-Fraction High-Dose-Rate Brachytherapy for Low- and Intermediate-Risk Prostate Cancer","volume":"104","author":"Siddiqui","year":"2019","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"key":"10.1016\/j.radonc.2024.110181_b0070","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1186\/s13014-018-1112-0","article-title":"ONE SHOT - single shot radiotherapy for localized prostate cancer: study protocol of a single arm, multicenter phase I\/II trial","volume":"13","author":"Zilli","year":"2018","journal-title":"Radiation Oncology"},{"key":"10.1016\/j.radonc.2024.110181_b0075","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.radonc.2019.07.018","article-title":"Single fraction urethra-sparing prostate cancer SBRT: Phase I results of the ONE SHOT trial","volume":"139","author":"Zilli","year":"2019","journal-title":"Radiotherapy and Oncology"},{"key":"10.1016\/j.radonc.2024.110181_b0080","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.radonc.2020.12.013","article-title":"Single-fraction prostate stereotactic body radiotherapy: Dose reconstruction with electromagnetic intrafraction motion tracking","volume":"156","author":"Jaccard","year":"2021","journal-title":"Radiotherapy and Oncology"},{"key":"10.1016\/j.radonc.2024.110181_b0085","doi-asserted-by":"crossref","first-page":"e353","DOI":"10.1016\/j.ijrobp.2012.01.023","article-title":"Pelvic normal tissue contouring guidelines for radiation therapy: a Radiation Therapy Oncology Group consensus panel atlas","volume":"83","author":"Gay","year":"2012","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"key":"10.1016\/j.radonc.2024.110181_b9000","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1200\/JCO.1998.16.1.139","article-title":"Interpreting the significance of changes in health-related quality-of-life scores","volume":"16","author":"Osoba","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2024.110181_b0090","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.radonc.2017.06.014","article-title":"Single-dose high-dose-rate brachytherapy compared to two and three fractions for locally advanced prostate cancer","volume":"124","author":"Hoskin","year":"2017","journal-title":"Radiotherapy and Oncology"},{"key":"10.1016\/j.radonc.2024.110181_b0095","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1001\/jamaoncol.2021.0039","article-title":"Safety and Efficacy of Virtual Prostatectomy With Single-Dose Radiotherapy in Patients With Intermediate-Risk Prostate Cancer: Results From the PROSINT Phase 2 Randomized Clinical Trial","volume":"7","author":"Greco","year":"2021","journal-title":"JAMA Oncology"},{"key":"10.1016\/j.radonc.2024.110181_b0100","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.brachy.2018.06.002","article-title":"High-dose-rate interstitial brachytherapy as monotherapy in one fraction of 20.5 Gy for the treatment of localized prostate cancer: Toxicity and 6-year biochemical results","volume":"17","author":"Prada","year":"2018","journal-title":"Brachytherapy"},{"key":"10.1016\/j.radonc.2024.110181_b0105","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.radonc.2020.02.009","article-title":"Prostate high dose-rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: Efficacy results from a randomized phase II clinical trial of one fraction of 19 Gy or two fractions of 13.5 Gy","volume":"146","author":"Morton","year":"2020","journal-title":"Radiotherapy and Oncology"},{"key":"10.1016\/j.radonc.2024.110181_b0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.109807","article-title":"Long-term outcomes of ultra-hypofractionated 2 fractions single day HDR brachytherapy in localized prostate cancer","volume":"186","author":"Nagore","year":"2023","journal-title":"Radiotherapy and Oncology"},{"key":"10.1016\/j.radonc.2024.110181_b0115","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.radonc.2019.12.017","article-title":"Single dose high-dose rate (HDR) brachytherapy (BT) as monotherapy for localised prostate cancer: Early results of a UK national cohort study","volume":"143","author":"Tharmalingam","year":"2020","journal-title":"Radiotherapy and Oncology"},{"key":"10.1016\/j.radonc.2024.110181_b0120","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.radonc.2016.10.019","article-title":"Prostate high dose-rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: Early toxicity and quality-of life results from a randomized phase II clinical trial of one fraction of 19Gy or two fractions of 13.5Gy","volume":"122","author":"Morton","year":"2017","journal-title":"Radiotherapy and Oncology"},{"key":"10.1016\/j.radonc.2024.110181_b0125","doi-asserted-by":"crossref","first-page":"3287","DOI":"10.1007\/s00345-023-04579-6","article-title":"State of the art and future challenges of urethra-sparing stereotactic body radiotherapy for prostate cancer: a systematic review of literature","volume":"41","author":"Le Guevelou","year":"2023","journal-title":"World Journal of Urology"},{"key":"10.1016\/j.radonc.2024.110181_b0130","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/0360-3016(91)90173-2","article-title":"Histogram reduction method for calculating complication probabilities for three-dimensional treatment planning evaluations","volume":"21","author":"Kutcher","year":"1991","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"key":"10.1016\/j.radonc.2024.110181_b0135","doi-asserted-by":"crossref","first-page":"S123","DOI":"10.1016\/j.ijrobp.2009.03.078","article-title":"Radiation dose-volume effects in radiation-induced rectal injury","volume":"76","author":"Michalski","year":"2010","journal-title":"International Journal of Radiation Oncology, Biology, Physics"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814024001026?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814024001026?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T05:28:54Z","timestamp":1759123734000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814024001026"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":28,"alternative-id":["S0167814024001026"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2024.110181","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ONE SHOT - single shot radiotherapy for localized prostate cancer: 18-month results of a single arm, multicenter phase I\/II trial","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2024.110181","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"110181"}}